AIM
TVRD

Alambic Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Alambic Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,358
Closed -$304K – 592
2016
Q1 		$304K Buy
+1,358
New +$406K 0.1% 321

Other funds holding TVRD

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alambic Investment Management's TVRD Position: Q2 2016 in Review

Alambic Investment Management sold out of Tvardi Therapeutics (TVRD) in Q2 2016, closing a stake of 1,358 shares — an estimated $304K sold.

Alambic Investment Management first reported a position in TVRD in Q1 2016 and held it in 1 quarter. The position peaked at $304K in Q1 2016. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

  • Alambic Investment Management reported no remaining Tvardi Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Alambic Investment Management sold 1,358 Tvardi Therapeutics shares in Q2 2016, an estimated $304K.
  • Alambic Investment Management first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 1 quarter.
  • Alambic Investment Management's Tvardi Therapeutics position peaked at $304K in Q1 2016.
  • 70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on Alambic Investment Management's 13F filing for Q2 2016, filed 8 Aug 2016.